JP7138351B2 - エクトヌクレオチダーゼ阻害剤およびその使用方法 - Google Patents

エクトヌクレオチダーゼ阻害剤およびその使用方法 Download PDF

Info

Publication number
JP7138351B2
JP7138351B2 JP2019533622A JP2019533622A JP7138351B2 JP 7138351 B2 JP7138351 B2 JP 7138351B2 JP 2019533622 A JP2019533622 A JP 2019533622A JP 2019533622 A JP2019533622 A JP 2019533622A JP 7138351 B2 JP7138351 B2 JP 7138351B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
amino
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504735A (ja
JP2020504735A5 (OSRAM
Inventor
ローランド ジョセフ ビレドー，
ジム リー，
リジン チェン，
Original Assignee
キャリセラ バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャリセラ バイオサイエンシーズ， インコーポレイテッド filed Critical キャリセラ バイオサイエンシーズ， インコーポレイテッド
Publication of JP2020504735A publication Critical patent/JP2020504735A/ja
Publication of JP2020504735A5 publication Critical patent/JP2020504735A5/ja
Application granted granted Critical
Publication of JP7138351B2 publication Critical patent/JP7138351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019533622A 2016-12-22 2017-12-21 エクトヌクレオチダーゼ阻害剤およびその使用方法 Active JP7138351B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662437935P 2016-12-22 2016-12-22
US201662437915P 2016-12-22 2016-12-22
US62/437,935 2016-12-22
US62/437,915 2016-12-22
US201762555791P 2017-09-08 2017-09-08
US62/555,791 2017-09-08
PCT/US2017/067980 WO2018119284A1 (en) 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2020504735A JP2020504735A (ja) 2020-02-13
JP2020504735A5 JP2020504735A5 (OSRAM) 2021-02-04
JP7138351B2 true JP7138351B2 (ja) 2022-09-16

Family

ID=62627279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533622A Active JP7138351B2 (ja) 2016-12-22 2017-12-21 エクトヌクレオチダーゼ阻害剤およびその使用方法

Country Status (12)

Country Link
US (3) US10570167B2 (OSRAM)
EP (1) EP3558998A4 (OSRAM)
JP (1) JP7138351B2 (OSRAM)
KR (1) KR102638592B1 (OSRAM)
CN (1) CN110402249A (OSRAM)
AU (1) AU2017382888B2 (OSRAM)
CA (1) CA3047988A1 (OSRAM)
IL (1) IL267291B2 (OSRAM)
MX (1) MX383880B (OSRAM)
NZ (1) NZ754171A (OSRAM)
TW (1) TWI766923B (OSRAM)
WO (1) WO2018119284A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529172A (ja) * 2018-06-21 2021-10-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤及びその使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CN110402249A (zh) 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
SG10202111869SA (en) 2017-07-31 2021-11-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
SG11202010790XA (en) 2018-04-30 2020-11-27 Oric Pharmaceuticals Inc Cd73 inhibitors
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
CA3133078A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
CN113874397A (zh) 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
US20220251134A1 (en) * 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
AU2020294724A1 (en) * 2019-06-20 2022-01-20 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
JP7544815B2 (ja) 2019-10-30 2024-09-03 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
JP7381913B2 (ja) * 2021-10-13 2023-11-16 ダイキン工業株式会社 有害生物防除組成物
EP4422643A4 (en) * 2021-10-26 2025-11-26 Southern Res Inst DEVELOPMENT OF NEW CLOFARABINE ANALOGUES FOR CANCER THERAPY
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019638A1 (en) 1991-04-24 1992-11-12 Yamasa Shoyu Kabushiki Kaisha 1-β-D-ARABINOFURANOSYL-(E)-5-(2-HALOGENOVINYL)-URACIL DERIVATIVE
AU5449094A (en) 1992-11-02 1994-05-24 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
RU2130029C1 (ru) * 1994-12-13 1999-05-10 Тайхо Фармасьютикал Ко., Лтд. 3'-замещенные производные нуклеозида, способ их получения (варианты), лекарственное средство, способ лечения и профилактики
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
US8603998B2 (en) 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2012006351A1 (en) 2010-07-08 2012-01-12 Life Technologies Corporation In situ chemiluminescent substrates and assays
WO2012151142A2 (en) 2011-05-03 2012-11-08 Life Technologies Corporation Flash and glow 1,2-dioxetanes
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
KR102772803B1 (ko) * 2016-01-08 2025-02-24 아르커스 바이오사이언시즈 인코포레이티드 5'-뉴클레오티다아제, 엑토의 조절제, 및 이의 용도
CN110402249A (zh) 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
CN112888696B (zh) 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529172A (ja) * 2018-06-21 2021-10-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤及びその使用方法
JP7538047B2 (ja) 2018-06-21 2024-08-21 アンテンジーン セラピューティクス リミテッド エクトヌクレオチダーゼ阻害剤及びその使用方法

Also Published As

Publication number Publication date
TW201834665A (zh) 2018-10-01
US20180186827A1 (en) 2018-07-05
EP3558998A1 (en) 2019-10-30
MX2019007243A (es) 2019-09-06
KR20190114972A (ko) 2019-10-10
IL267291B (en) 2022-12-01
JP2020504735A (ja) 2020-02-13
NZ754171A (en) 2022-12-23
KR102638592B1 (ko) 2024-02-19
CA3047988A1 (en) 2018-06-28
US20230002437A1 (en) 2023-01-05
AU2017382888A1 (en) 2019-06-20
US20200223882A1 (en) 2020-07-16
MX383880B (es) 2025-03-14
WO2018119284A1 (en) 2018-06-28
TWI766923B (zh) 2022-06-11
EP3558998A4 (en) 2020-06-10
IL267291B2 (en) 2023-04-01
BR112019012327A2 (pt) 2019-11-19
US11034715B2 (en) 2021-06-15
CN110402249A (zh) 2019-11-01
US10570167B2 (en) 2020-02-25
AU2017382888B2 (en) 2021-12-23
IL267291A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP7138351B2 (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
JP7125144B2 (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
US12421273B2 (en) Ectonucleotidase inhibitors and methods of use thereof
JP2022537358A (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220830

R150 Certificate of patent or registration of utility model

Ref document number: 7138351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250